International Journal of Hematology

DOI: 10.1007/s12185-018-02577-8 Pages: 1-3

Ibrutinib in Japanese patients with relapsed/refractory B-cell malignancies: final analysis of phase I study

1. National Cancer Center Hospital, Department of Hematology

2. Japanese Red Cross Nagoya Daini Hospital

3. Tohoku University Hospital

4. Janssen Pharmaceutical K.K.

Correspondence to:
Kensei Tobinai
Tel: +81-3-3542-2511
Email: ktobinai@ncc.go.jp

Close

Abstract

To access the full text, please Sign in

If you have institutional access, please click here

Share the Knowledge